Nurix Therapeutics
- Market cap
- 2.36B
- P/E (TTM)i
- -6.57
- P/Bi
- 5.86
- EPSi
- -3.05
- Div yieldi
- 0.00%
- 52W posi
- 71%
Anonymous reader poll. Unscientific, not investment advice.
Nurix Therapeutics ended the session at 22.73, up 0.58%. Its market capitalisation is about 2.36B, the #2679 most valuable US-listed company we track. Across 10 analysts the consensus rating is Buy, with an average price target of 34.50 (+52%). Against a 52-week band of 9.00-28.23, the shares are currently 71% of the way up.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 4% of the universe, above its 200-day average.
- Signal has read BUY for 4 months.
- Recent price momentum is +62.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 17.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 22.60
- Open
- 22.43
- Day range
- 22.18 - 23.10
- Avg price
- 22.76
- Volume
- 1.63M
- Turnover
- 37.15M
- Turnover ratei
- 2.20%
- Volume ratioi
- 1.19
- Amplitudei
- 4.07%
- 52-week rangei
- 9.00 - 28.23
Valuation
- P/Ei
- -7.45
- P/E (TTM)i
- -6.57
- P/Bi
- 5.86
- EPSi
- -3.05
- Book value / shi
- 3.88
- Net profit
- -316.53M
- Net assets
- 402.67M
Share structure
- Market cap
- 2.36B
- Float capi
- 1.68B
- Shares out
- 103.78M
- Float sharesi
- 74.11M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-07-24
19.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-23.97M net over the window
Short interest
- Shares short
- 17.98M
- % of floati
- 17.32%
- Days to coveri
- 14.05
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Nurix Therapeutics (NRIX)?
Nurix Therapeutics last traded at 22.73. The quote on this page refreshes every few seconds while US markets are open.
What is Nurix Therapeutics's market cap?
About 2.36B.
What is the P/E ratio of Nurix Therapeutics?
The trailing twelve-month P/E is -6.57. The Valuation tab shows it against the stock's own five-year range.
Does Nurix Therapeutics pay a dividend?
Nurix Therapeutics does not currently pay a regular dividend.
Is Nurix Therapeutics a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 34.50, which implies 51.8% upside from the current price. This is not investment advice.
What is Nurix Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Nurix Therapeutics a B (Buy). Twelve-month momentum in the top 4% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 06:18:54 · For reference only, not investment advice and not tailored to your situation.